Chimeric Therapeutics (ASX:CHM)
ASX announcement history & article coverage
Transparent by design.
Announcments by Chimeric Therapeutics (ASX:CHM) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ceasing to be a substantial holder from MFG
Notice of initial substantial holder from MFG
Final Director's Interest Notice - LR
Final Director's Interest Notice - BG
Initial Director's Interest Notice - RM
FY2026 Annual Report, creditor update and Board changes
Chimeric remains suspended amid creditor negotiations, $7.7 million net asset deficiency and board overhaul
Application for quotation of securities - CHM
Application for quotation of securities - CHM
Application for quotation of securities - CHM
Appendix 4E and Preliminary Final Report
Application for quotation of securities - CHM
Application for quotation of securities - CHM
CHM ceases enrolment in Phase 1 trial and Company update
Trading Halt
Application for quotation of securities - CHM
Quarterly Activities/Appendix 4C Cash Flow Report
Chimeric Therapeutics reports positive clinical progress, capital consolidation, and strategic review with $0.8M cash at June 2026
Chimeric receives $1.62M advance on FY26 R&D tax incentive
Chimeric Therapeutics secures $1.62M advance on FY26 R&D tax incentive to fund clinical trials
Investor Presentation
Application for quotation of securities - CHM